Interstiziopatia polmonare, una nuova rara tossicità indotta da oxaliplatino: segnalazione di un caso e valutazione della relazione causale ADR-Farmaco.

Oxaliplatin (L-OHP) in combination with 5-fluorouracil (5-FU) and leucovorin (FOLFOX) has been approved for advanced colorectal cancer and for adjuvant treatment of people with stage III colon cancer. The information concerning the pulmonary toxicity of this regimen is very limited. We report here a clinical case of a patient in local Lanciano Hospital admitted with interstitial lung disease (ILD) following the postoperative treatment with L-OHP and 5-FU according to the FOLFOX- 4 schedule of a metastatic rectum-sigma. Naranjo and Jones algoritms suggest a direct causal relationship. Our case adds to the form patients reported so far in the literature following the FOLFOX protocol. Despite this apparent rarity, the risk of ILD should be taken in due consideration: when a patient treated by chemotherapy presents with early signs of respiratory distress (the progressive or abrupt development of nonproductive cough, fever, dyspnea) to avoid a irreversible respiratory failure